The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 18 of the 30 sources its claims cite were checked for support.
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Open accessAbstract
Importance: Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective: To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants: In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were randomized in a 1:1 ratio to receive a single dose of psilocybin vs niacin placebo administered with psychological support. Participants were adults aged 21 to 65 years with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition diagnosis of MDD of at least 60 days' duration and moderate or greater symptom severity. Exclusion criteria included history of psychosis or mania, active substance use disorder, and active suicidal ideation with intent. Participants taking psychotropic agents who otherwise met inclusion/exclusion criteria were eligible following medication taper. Primary and secondary outcomes and adverse events (AEs) were assessed at baseline (conducted within 7 days before dosing) and at 2, 8, 15, 29, and 43 days after dosing. Interventions: Interventions were a 25-mg dose of synthetic psilocybin or a 100-mg dose of niacin in identical-appearing capsules, each administered with psychological support. Main Outcomes and Measures: The primary outcome was change in central rater-assessed Montgomery-Asberg Depression Rating Scale (MADRS) score (range, 0-60; higher scores indicate more severe depression) from baseline to day 43. The key secondary outcome measure was change in MADRS score from baseline to day 8. Other secondary outcomes were change in Sheehan Disability Scale score from baseline to day 43 and MADRS-defined sustained response and remission. Participants, study site personnel, study sponsor, outcome assessors (raters), and statisticians were blinded to treatment assignment. Results: A total of 104 participants (mean [SD] age, 41.1 [11.3] years; 52 [50%] women) were randomized (51 to the psilocybin group and 53 to the niacin group). Psilocybin treatment was associated with significantly reduced MADRS scores compared with niacin from baseline to day 43 (mean difference,-12.3 [95% CI, -17.5 to -7.2]; P <.001) and from baseline to day 8 (mean difference, -12.0 [95% CI, -16.6 to -7.4]; P < .001). Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, -2.31 [95% CI, 3.50-1.11]; P < .001) from baseline to day 43. More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin. There were no serious treatment-emergent AEs; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs. Conclusions and Relevance: Psilocybin treatment was associated with a clinically significant sustained reduction in depressive symptoms and functional disability, without serious adverse events. These findings add to increasing evidence that psilocybin-when administered with psychological support-may hold promise as a novel intervention for MDD. Trial Registration: ClinicalTrials.gov Identifier: NCT03866174.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
45 Own result · 17 Own method · 8 Partly supported · 5 Own interpretation · 4 No full text of the sources · 3 Supported so far · 3 Couldn’t confirm · 2 No basis given · 1 Sources not found · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Psilocybin shows promise as a treatment for major depressive disorder (MDD).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Partly supportedcites [6] 6. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12): 1181-1197. doi:10.1177/0269881116675513 sourceExperimental — accuracy not yet measured
The Abstract reports substantial, sustained decreases in depressed mood after psilocybin, and Methods > Study participants says 18 of the 51 patients had an MDD diagnosis, including four also diagnosed with generalized anxiety disorder. But the results concern a mixed group of patients with life-threatening cancer and do not establish the effect specifically for MDD patients or for MDD more generally. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [7] 7. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155-166. doi:10.1177/ 0269881119897615 source
- Partly supportedcites [8] 8. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12): 1165-1180. doi:10.1177/0269881116675512 sourceExperimental — accuracy not yet measured
The Discussion (Primary outcomes; page unavailable) reports sustained reductions in depression symptoms among patients with life-threatening cancer and cites a separate open-label study in treatment-resistant depression. This supports the cautious phrase “shows promise,” but this trial did not test psilocybin as a treatment for MDD specifically; its participants had cancer-related distress and anxiety-related diagnoses (Methods, Study sample and setting; page unavailable). (LLM, conf=0.84)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Nonetheless, placebo response rates in the current study are smaller than are typically observed with daily placebo pills, 34 which may have inflated the placebo-adjusted effect size compared with studies of standard antidepressants in patients with MDD.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Could not verifycites [34] 34. Williams MT, Reed S, Aggarwal R. Culturally informed research design issues in a study of MDMA-assisted psychotherapy for posttraumatic stress disorder. J Psychedelic Stud. 2019;4(1):40-50. doi:10.1556/2054.2019.016 sourceExperimental — accuracy not yet measured
The Introduction contrasts MDMA given 2–3 times with medications often taken daily, but it does not compare placebo response rates. Searches for daily placebo pills, MDD, and placebo-adjusted effect size found no passage addressing the cited claim that placebo responses were smaller than those typically observed with daily pills. (LLM, conf=0.76)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The 8% rate of severe adverse events in participants receiving psilocybin was similar to the 10% rate reported in the study by Goodwin et al in participants with TRD treated with a single 25-mg dose of psilocybin.14”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
What the sources say
- Partly supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 sourceExperimental — accuracy not yet measured
The Safety section reports severe adverse events in 9% of the 25-mg group from day 2 through week 3, but does not report the claimed 10% rate. Table 3 also gives separate rates of 4% on day 1 and 3% after week 3; these interval-specific rates do not establish a 10% overall rate. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, the success of allocation blinding was not assessed, and it is likely that the acute psychoactive effects of psilocybin produced some degree of functional unblinding that may have contributed to the observed effect in psilocybin-treated (psilocybin -niacin).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Partly supportedcites [33] 33. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245. doi:10.1186/s12888-018- 1824-6 sourceExperimental — accuracy not yet measured
The Results > Study methodologies section says that finding a placebo that mimics psychedelics’ physiological effects is an important issue for double-blinded trials. That supports a general concern about blinding, but the paper does not say that psilocybin caused functional unblinding in the psilocybin–niacin comparison or that unblinding contributed to its observed effect. No page number is available in our copy. (LLM, conf=0.78)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Nonetheless, placebo response rates in the current study are smaller than are typically observed with daily placebo pills, 34 which may have inflated the placebo-adjusted effect size compared with studies of standard antidepressants in patients with MDD.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Could not verifycites [34] 34. Williams MT, Reed S, Aggarwal R. Culturally informed research design issues in a study of MDMA-assisted psychotherapy for posttraumatic stress disorder. J Psychedelic Stud. 2019;4(1):40-50. doi:10.1556/2054.2019.016 sourceExperimental — accuracy not yet measured
The Introduction describes MDMA-assisted psychotherapy for PTSD and contrasts its dosing schedule with medications taken daily, but it does not compare placebo response rates. Searches of our copy for daily placebo pills and placebo-adjusted effects found no passage addressing the claimed comparison. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and from baseline to day 8 (mean difference, -12.0 [95% CI, -16.6 to -7.4]; P < .001).”
- Also stated in: § Efficacy · plain
“and from baseline to day 8 (key secondary end point) (mean difference, -12.0 [95% CI, -16.6 to -7.4]; P < .001).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plaincorrelationaln = 104 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no serious treatment-emergent AEs”
- Also stated in: § Discussion · plain
“No serious TEAEs were reported in the current study”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plainn = 104- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“More participants receiving psilocybin than niacin had sustained depressive symptom response (20/48 [42%] vs 5/44 [11%]; adjusted absolute difference, 30.3 [95% CI, 13.5-47.1];P = .002;OR, 5.6 [95% CI, 1.9-16.7];P = .002)”
- Also stated in: § Abstract · plain
“More participants receiving psilocybin had sustained response (but not remission) than those receiving niacin.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and a higher rate of severe AEs.”
- Also stated in: § Safety · plain
“Severe related AEs through day 9 were reported by 4 of 50 participants (8%) receiving psilocybin (migraine in 1 participant, headache in 1 participant, illusion in 1 participant [all solicited], and panic attack and paranoia in 1 participant) vs 0 in the niacin group.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plaincorrelationaln = 50- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocybin treatment was also associated with significantly reduced Sheehan Disability Scale scores compared with niacin (mean difference, -2.31 [95% CI, 3.50-1.11];P < .001)from baseline to day 43.”
- Also stated in: § Efficacy · plain
“Mean change difference in SDSassessed functional disability score from baseline to day 43 was greater in the psilocybin vs niacin group (-2.31 [95% CI, 3.50-1.11];P < .001)”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
plaincorrelationaln = 104 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Efficacy · plain
- It may state two separate claims as one. 21
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent critiques highlight notable limitations in many of these studies, [16][17][18][19] including small sample sizes, assessments by raters likely to be functionally unblinded, an open or waitlist comparator design, and an inadequate assessment of adverse events (AEs).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Partly supportedcites [16] 16. Hall WD, Humphreys K. Is good science leading the way in the therapeutic use of psychedelic drugs? Psychol Med. 2022;52(14):2849-2851. doi: 10.1017/S0033291722003191 sourceExperimental — accuracy not yet measured
In “Lowering of standards by major medical journals” (page unavailable), the paper describes a psilocybin trial with 30 and 29 patients in its two arms, calls it underpowered, and questions whether participants remained blinded. It does not say that outcome raters were functionally unblinded or that the studies used open or waitlist comparators or inadequately assessed adverse events. The trial it discusses used escitalopram as its comparator. (LLM, conf=0.87)
- Partly supportedcites [17] 17. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100-1117. doi:10. 1177/02698811221116926 sourceExperimental — accuracy not yet measured
The Discussion > Limitations section (page unavailable) says the included studies were mostly small and that few assessed adverse events systematically. The Psilocybin section identifies open-label studies, and the Limitations section notes difficulty blinding participants. Our copy does not establish that outcome raters were functionally unblinded or that studies used waitlist comparators. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [18] 18. Yaden DB, Potash JB, Griffiths RR. Preparing for the bursting of the psychedelic hype bubble. JAMA Psychiatry. 2022;79(10):943-944. doi:10.1001/ jamapsychiatry.2022.2546 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Larger recent studies have addressed these issues to various degrees, but report primary end points of short duration, 14,15 leaving open the question of the long-term clinical utility of psilocybin for an often chronic condition such as MDD.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 source
The Discussion says this trial addressed limitations of earlier studies and had a primary end point at 3 weeks, despite 12 weeks of follow-up. The Abstract says larger and longer trials are needed to determine psilocybin’s efficacy and safety for treatment-resistant depression, supporting the claim that its longer-term clinical utility remains open. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [15] 15. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. doi:10.1016/j. eclinm.2022.101809 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“recent studies suggesting that psilocybin engenders a rapid antidepressant response that far outlasts the presence of the drug in the body.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Abstract
What the sources say
- Partly supportedcites [6] 6. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12): 1181-1197. doi:10.1177/0269881116675513 sourceExperimental — accuracy not yet measured
The Results (Outcome measures; page unavailable) report a substantial antidepressant response in patients with life-threatening cancer at five weeks, sustained at six months. The Methods (Outcome measures; page unavailable) say the subjective drug effects had subsided by seven hours, supporting that the benefit outlasted the acute effects. But depression was first assessed five weeks after dosing, so this study does not establish how rapidly the antidepressant response began or when the drug left the body. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [7] 7. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155-166. doi:10.1177/ 0269881119897615 source
- Partly supportedcites [8] 8. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12): 1165-1180. doi:10.1177/0269881116675512 sourceExperimental — accuracy not yet measured
The Discussion (Primary outcomes) reports immediate antidepressant effects lasting weeks to months after a single psilocybin dose, given with psychotherapy to patients with life-threatening cancer. The paper does not establish how long the drug remains in the body, so the comparison with its bodily presence is not directly supported. (LLM, conf=0.82)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“First, the success of allocation blinding was not assessed, and it is likely that the acute psychoactive effects of psilocybin produced some degree of functional unblinding that may have contributed to the observed effect in psilocybin-treated (psilocybin -niacin).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Partly supportedcites [33] 33. Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18(1):245. doi:10.1186/s12888-018- 1824-6 sourceExperimental — accuracy not yet measured
The Results > Study methodologies section (page unavailable) says that a placebo must mimic psychedelic effects for a double-blinded trial, supporting the general concern about blinding. It does not report functional unblinding in a psilocybin–niacin comparison or link it to treatment effects or niacin-group dropout. (LLM, conf=0.82)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one. The quote only partly states this claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Niacin was used as an active placebo that produces an acute physiological response (flushing) thought to aid in blinding.8,22”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
What the sources say
- Partly supportedcites [8] 8. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12): 1165-1180. doi:10.1177/0269881116675512 sourceExperimental — accuracy not yet measured
The Methods section (Study design and interventions; page unavailable) identifies niacin as the active control in a double-blind psilocybin trial. Our copy does not state that niacin caused flushing or that this physiological response was intended to aid blinding; the section refers readers to supplementary blinding procedures without describing them. (LLM, conf=0.84)
- Could not verifycites [22] 22. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603-620. doi:10. 1177/0269881108093587 sourceExperimental — accuracy not yet measured
The Preparation of volunteers section discusses blinding and an active placebo, but identifies that placebo as methylphenidate. Searches for niacin and flushing found no passage in our copy addressing niacin’s use, its physiological response, or whether it aided blinding. (LLM, conf=0.72)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Second, the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response, given that placebo response rates in the current study were equivalent to those seen in response to a low-dose psilocybin comparator in participants with TRD and larger than the effect of an inactive placebo in a recent study in participants with MDD.14,15”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 source
The Efficacy section reports an 18% response rate at week 3 in the 1-mg psilocybin comparator group among participants with treatment-resistant depression. That supports the low-dose comparator figure used in the citing paper's comparison; this source is not offered as evidence for the citing study's own placebo rate or the separate MDD study. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [15] 15. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. doi:10.1016/j. eclinm.2022.101809 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Niacin 100 mg is an inactive placebo with no antidepressant effect.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“No serious TEAEs were reported in the current study; however, psilocybin treatment was associated with a higher rate of overall AEs and a higher rate of severe AEs compared with niacin, with these severe AEs being known effects of psilocybin.17”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
What the sources say
- Partly supportedcites [17] 17. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review. J Psychopharmacol. 2022;36(10):1100-1117. doi:10. 1177/02698811221116926 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Moreover, psychedelics may produce AEs not captured by standard rating scales or may induce unrecognized new psychiatric conditions even as they improve target syndromes.32”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
What the sources say
- Could not verifycites [32] 32. Jones BDM, Razza LB, Weissman CR, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(9):e2125531. doi:10.1001/jamanetworkopen.2021.25531 sourceExperimental — accuracy not yet measured
The Results (page not provided) list an ayahuasca trial and the depression rating scale it used, but do not discuss psychedelic adverse events or new psychiatric conditions. A search of our copy for those risks and for limitations of standard rating scales found no passage addressing the claim. (LLM, conf=0.76)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Second, the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response, given that placebo response rates in the current study were equivalent to those seen in response to a low-dose psilocybin comparator in participants with TRD and larger than the effect of an inactive placebo in a recent study in participants with MDD.14,15”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
What the sources say
- Supportedcites [14] 14. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022; 387(18):1637-1648. doi:10.1056/NEJMoa2206443 source
The citation supports the comparison to a low-dose psilocybin group in participants with treatment-resistant depression: the Efficacy section reports an 18% response rate at week 3 in the 1-mg group. The suggestion that niacin increased comparator believability and placebo response is the citing authors’ own explanation, not a finding attributed to this paper. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [15] 15. von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2022;56:101809. doi:10.1016/j. eclinm.2022.101809 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sustained depressive symptom remission rate appeared greater with psilocybin, but the difference was not statistically significant (12/48 [25%] for psilocybin vs 4/44 [9.1%] for niacin; adjusted absolute difference, 15.9 [95% CI, 1.0-30.8];P = .05;OR, 3.4 [95% CI, 1.0-11.5])”
- Also stated in: § Discussion · plain
“The 15.9% difference in sustained remission rates between the groups was not significantly different.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 1529 potential participants who completed prescreening, 347 signed informed consent, 240 were excluded at screening, 3 were excluded prior to randomization, and 104 were randomized, received the study drug, and comprised the ITT population (51 in the psilocybin group and 53 in the niacin group)”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Participants
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of mild and moderate drug-related TEAEs in the same period were higher for psilocybin vs niacin (mild: difference, 35% [95% CI, 17.9%-52.9%];RI, 1.8 [95% CI, 1.1-1.8]);moderate: difference, 18% [95% CI, 5.8%-30.8%];RI, 2.3 [95% CI, 1.0-5.7]).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Visual perceptual effects (assessed following resolution of acute drug effects) were reported by 22/50 (44%) psilocybin participants on the day of dosing and by 3/50 (6%) after the dosing day, all resolved by study conclusion”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plainn = 50- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on C-SSRS or MADRS Item 10 scores and confirmed by clinical assessment, no suicidal or self-injurious behavior occurred during the trial and all instances of suicidal ideation were considered passive.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocybin treatment was associated with improvements in various exploratory end points, including reductions in global disease severity, self-reported depressive and anxiety symptoms, and improvement in quality of life, while having no effect on emotional blunting”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three serious AEs occurred between enrollment and randomization (nephrolithiasis; incisional hernia, obstructive; and appendicitis; Table 3).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Severe solicited events were reported by 3 participants receiving psilocybin (2 headaches and 1 visual perceptual effects) and 1 headache was reported in a participant receiving niacin.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In contrast to prior psilocybin trials for depression, 8,14,15 there was not a significant reduction in depressive symptoms or a psilocybin/ placebo difference in depressive symptom status at the day 2 assessment (ie, 1 day after dosing)”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Randomization was administered centrally by the study's clinical research organization via the Advantage eClinical data system.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“One participant randomized to receive psilocybin received the incorrect treatment, resulting in 50 participants receiving psilocybin and 54 receiving niacin.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Participants
plaindirectSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary efficacy analysis was a de facto estimand conducted on the intent-to-treat (ITT) population that included all randomized participants analyzed according to randomized treatment group.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“By 6 weeks, 1 participant in the psilocybin group and 9 in the niacin group had withdrawn or been lost to followup”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Participants
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Psilocybin was generally well-tolerated, with most AEs being of mild or moderate severity and generally limited to the acute dosing period.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“No procedure for α-level control was applied for exploratory end points, therefore P values reported for these outcomes in eTables 4-8 in Supplement 3 should be considered nominal (ie, not adjusted for multiple comparisons).”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Participants, study sponsor, and study site personnel were blinded to treatment group until unblinding following data lock.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Similarly, the current study does not allow inferences to be drawn regarding whether the antidepressant effect would have diminished over subsequent weeks or been maintained”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“a sample size of 100 participants resulted in 92% power for the primary day 43 end point and 98% power for the key secondary day 8 end point.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plainn = 100- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“A minimal clinically important difference (MCID) in change in MADRS score was not prespecified, although depression trial literature supports a placebo-adjusted change in score as low as 2 and as high as 9 and an absolute change from pretreatment of 6 as clinically meaningful and a change of 12 as clinically substantial.25,26”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Efficacy Assessments
What the sources say
- Not checked — no full text of the sourcecites [25] 25. Hengartner MP, Plöderl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid Based Med. 2022;27(2):69-73. doi:10.1136/ bmjebm-2020-111600 source
- Not checked — no full text of the sourcecites [26] 26. Kobak KA, Williams JB, Jeglic E, Salvucci D, Sharp IR. Face-to-face versus remote administration of the Montgomery-Asberg Depression Rating Scale using videoconference and telephone. Depress Anxiety. 2008;25(11):913-919. doi:10.1002/da.20392 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“eligible participants were randomized in a 1:1 ratio using permuted blocks with random block sizes of 2, 4, and 6, with randomization stratified by site”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Study Procedures
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To help address this issue, the current study used off-site centralized raters to reduce the potential impact of unblinding on the assessment of outcomes.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Limitations
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A sequential significance testing procedure was used to control the overall α level at .05 for primary and secondary end points.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sensitivity analyses using multiple imputation methods were run for the primary and key secondary outcomes.”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Statistical Analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
Niacin 100 mg is an inactive placebo with no antidepressant effect.
“compared with a 100-mg dose of niacin placebo administered under an identical protocol.”
“the use of niacin as active placebo may have increased believability of the comparator condition and enhanced the placebo response”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In some instances, control groups consisted of waiting lists rather than active comparators, 60,73 and therapeutic settings were sometimes not consistently provided. 74,76”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Blinding procedures were not consistently robust, 26,32,60,72-76 and comparison with placebo or standard treatments was lacking in many studies. 25,26,31-33,39,57,60,72,73,75-81”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [76]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Safety
“difference, 38% [95% CI, 20.6%-41.3%]”
§ Single-Dose Psilocybin Treatment for Major Depressive Disorder A Randomized Clinical Trial > Conclusions
“| At least 1 related AE c | 41 (82) | 24 (44) | 41 (82) | 24 (44) | 38 (20.6 to 54.6) 2 (4) | 1 (2) | 2 (-4.4 to 8.7) | |”
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Self-citationSingle-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
Self-citation
Cited by
Sorted by citations
Items 401–500 of 531
Rangan, R. S., Petty, R. M., Acharya, S., Emmitte, K. A., do Valle, R., Lam, C., Essajee, S. I., Mayhew, W., Young, O., Brooks, C. D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.13.638188
Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Major Depressive Disorder (MDD) Treatment
He, Q., Bennett, A. N., & Chan, K. H. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-32035-4_28-1
Quah, S. K. L., Glick, C., Roseman, L., Pasquini, L., Carhart-Harris, R. L., & Saggar, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.05.641592
Supervised Machine-Learning Classification of Treatment-Resistant Depression in U.S. Claims DataPreprint
Wing, V. K., Lerner, J., Clarke, P., O’Connor, S. J., Tran, S., Darer, J. D., Gill, J. S., & Orsini, L. S. (2025) · medRxiv · doi:10.1101/2025.03.26.25324691
Exploring psilocybin’s role in mental health and palliative medicine: a path to improved well-being
Umbacia, M. A., León, M., Quintero, J.-M., Castro, L.-M., Páez, V., Dodd, S., & Bustos, R. (2025) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2025.2488786
Totomanova, I., Haijen, E. C. H. M., Hurks, P. P. M., Ramaekers, J. G., & Kuypers, K. P. C. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.002
Psychedelics for Depression: Between Hopes and Uncertainties
Suppes, T., & Fradet, M. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250005
Clarifying the Concept of Psychological Support in Psychedelic Clinical TrialsPreprint
Schettino, J. R., Cheung, K., Nayak, S. M., & Yaden, D. B. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5225420
Self-citationJoseph, K., Collins, J., Genovese, T. S., Maxwell, M., LIEBERMAN, J., & Osten, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.26.655791
ADVANCES IN TREATING DEPRESSION
Director of Pharmacy (retd.), S. J. C. M. H. S., & Tutupalli, L. V. (2025) · INDIAN DRUGS · doi:10.53879/id.62.06.15334
Explore the effect of psilocybin on depression and anxiety
Song, Y. (2025) · Arts Culture and Language · doi:10.61173/rcg8me57
Recent advances in rapid-acting antidepressants
Pan, L., He, Y., Wang, G., & Shen, J. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0157
Psychedelics‐Inspired Drug Discovery
Gibbs, A., & Khan, T. A. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch3
Preparing Social Work for Psychedelic-Assisted Therapy
ALLEN, H. L., & Stott, B. L. (2025) · Social Work · doi:10.1093/sw/swaf031
The 5-HT1B Autoreceptor's Role in Emotional Processing in Relation to Acute Psilocybin ExperiencesPreprint
Malinak, M., & Beach, K. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5377073
The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives
Rahmani, S., Crupi, R., Riley, A. L., & Davidson, T. L. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174087
Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Major Depressive Disorder (MDD) Treatment
He, Q., Bennett, A. N., & Chan, K. H. K. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_28
Psychedelic studies in nonhuman primates: Past and future
Masthay, J. C., Kwan, A. C., & Chang, S. W. C. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03240-5 · Cited by 2
“These effects persisted for 14 days after DMT administration, potentially mirroring the long-term reductions in depressive behaviors seen after single administrations of psychedelics in some human studies [2, 3, 108].”
Zhang, X., Liu, D.-N., Miao, Q.-S., Cai, X., Zong, L.-X., Hou, Y.-K., & Xiong, J. (2025) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2025.174099
Self-Integration after Recreational Psychedelic Use: Is it a Bulwark against Identity Disturbance?
Versace, J., & Rucker, J. (2025) · Journal of Humanistic Psychology · doi:10.1177/00221678251369932
McConnell, P., Raffety, J., Li, A., Steinberg, E., Rahim, S., Valtierra, C., Gazzaley, A. H., Carhart-Harris, R. L., & Pasquini, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7625999/v1
Psilocybin’s effect on human brain synaptic plasticityPreprint
Knudsen, G. M., Johansen, A., Plavén‐Sigray, P., Madsen, M. K., Søndergaard, A., Messell, C., Geisler, M., Nasser, A., McCulloch, D. E.-W., Beliveau, V., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7469144/v1
Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review
de Oliveira, A. L., de Oliveira, D. P., SANTOS, R. G. D., & Hallak, J. E. C. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111534
Borbón, D. (2025) · Revista de Bioética y Derecho · doi:10.1344/rbd2025.65.49541
McGuigan, A. (2025) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01199-5
Machado, T. L. G. N., Rodrigues, A. S. L., & Costa, J. N. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251397590
Psilocybin reporting in media (PRiMe) for the treatment of depression
Brar, G., Burke, T., Gribben, A. D., Harrington, C., Thuery, G., & Kelly, J. R. (2025) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2025.10142
“…in the number of clinical studies, which in turn suggests a growing acceptance of psychedelic research, particularly as positive findings from clinical trials have emerged (Carhart-Harris et al. 2021; Goodwin et al. 2022; 2025; Gukasyan et al. 2022; Raison et al. 2023; von Rotz et al. 2023).”
Edible Mushrooms: Structure, Key Compounds, and Biological Effects
Broderick, M.-Z. L., Khan, R. Q., & Siwoku, O. O. (2025) · Nutritional neurosciences · doi:10.1007/978-981-95-2774-8_2
Gordon, A. R., Carrithers, B. M., Pagni, B. A., Kettner, H., MRes, A. M., Nayak, S. M., Weiss, B., Carhart-Harris, R. L., Roberts, D. E., Erritzøe, D., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251382930
Self-citationSuggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy
Lappan, S. N., & Davis, S. D. (2025) · Psychedelic Medicine · doi:10.1177/28314425251404021 · Cited by 2
Past-Year Lysergic Acid Diethylamide Use in United States Sexual Minorities from 2015 to 2019
Barnett, B. S., Anand, A., Falcone, T., Altinay, M. I., Dewey, E. N., & Weleff, J. (2025) · Psychedelic Medicine · doi:10.1177/28314425251410086
Psilocybin and Bipolar Depression: Promise and Prudence
Marques, M. G., Patarroyo-Rodríguez, L., & Singh, B. (2026) · CNS Drugs · doi:10.1007/s40263-025-01255-8
Fungal-derived supplements in integrative oncology
Mohammed, C., Aaroe, A., Buchold, G., Krummel, D. P., Stamets, P. E., Sharma, A. V., Alschuler, L. N., & Sengupta, S. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.12.028
Blaise, C. R. (2026) · Synthese · doi:10.1007/s11229-026-05443-x
“…studies, reviews, and meta-analyses (Perez et al., 2023 ; Sanches et al., 2016 ; Davis et al., 2021 ; Rucker et al., 2016 ; Goodwin et al., 2023 ; Raison et al., 2023 ; dos; San-tos et al., 2016 ) have demonstrated that psychedelics significantly reduce depressive symptoms in cases of both…”
The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review
Siwek, L., Nowocień, M., Balajewicz, B., Samborska, A., Szukalska, S., Karczewska, M., Lichwala, K., Wroblewski, K., & Wróblewska, P. (2026) · Cureus · doi:10.7759/cureus.102694
“Finally, a study published in 2023 is discussed [37].”
Ben‐Zion, Z., Simon, G., & Lazebnik, T. (2026) · Research Square · doi:10.21203/rs.3.rs-8682370/v1
Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C., Bergman, R. L., Shapiro, B., Barnett, G., Artin, H., Lynn, M., Salimian, A., Grody, S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121423 · Cited by 1
Montoy, J. C. C., Wang, R. C., Coker, A. R., & Anderson, B. T. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113059
Chemické látky a jejich biologické účinky
Hradil, P., & Soural, M. (2025) · doi:10.5507/prf.25.24466682
Predictors of the Effectiveness of Psychedelics in Treating Depression—A Scoping Review
Chmiel, J., & Rybakowski, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052202 · Cited by 1
“Multiple randomised controlled trials (RCTs) in patients with major depression have demonstrated that adjunct psilocybin therapy yields significantly greater symptom improvements than control conditions (placebo or conventional treatments) [8,9].”
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
Williamson, S. E., Burkhartzmeyer, E. K., Faley, M. T., Ohana, R. F., Guzei, I. A., Valley, M., Cali, J. J., & Sherwood, A. M. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00879
Mushroom biotech startups help address global challenges
Lurie‐Luke, E. (2026) · Nature Communications · doi:10.1038/s41467-026-70167-y
Psychological support in psychedelic-assisted therapy clinical trials: A systematic review
Brusky, B., M’Baïlara, K., Alla, F., & Barrault, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261424204 · Cited by 1
“Rather, it serves to encourage “inward reflection” (Davis et al., 2021; Raison et al., 2023).”
InfluentialSkalski, P., Pękacka‐Falkowska, K., Pluto-Prądzyńska, A., & Owecki, M. K. (2026) · Brain Sciences · doi:10.3390/brainsci16040358
“Cultural and socioeconomic factors (e.g., healthcare access, social support, educational level) may influence the perception and evaluation of psychedelic effects, an issue recognized by the authors themselves [29].”
Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory CortexPreprint
Johnson, J. D., Tian, R., Etemadi, Y., & Li, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.26.714498
Gu, E. Y., Irvine, N. M., Miller, M. J., Ramirez, E., Santaella-Tenorio, J., Lippincott, T., Bogenschutz, M. P., Bunting, A. M., Meacham, M. C., & Krawczyk, N. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00487
Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use
Bhatt, K. V., Friedman, J., Benster, L. L., Narasimhan, R., Yang, K., Mishra, J., Weissman, C. R., & Ramanathan, D. (2026) · Community Mental Health Journal · doi:10.1007/s10597-026-01620-x
“…has been a resurgence of interest from scientists and clinicians (Carhart-Harris & Goodwin, 2017; Goodwin et al., 2022 ; Griffiths et al., 2008 ; Raison et al., 2023 ) due to promising findings on their therapeutic effects in neuropsychiatric disorders, and the recognized need for novel and…”
Meshkat, S., Jha, M. K., & Bhat, V. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20250043
Aday, J. S., Glynos, N. G., Baker, A. K., Pouyan, N., Smith, T., Barron, J., Herberholz, M., Kruger, D. J., Woolley, J. D., & Boehnke, K. F. (2026) · Scientific Reports · doi:10.1038/s41598-026-48084-3 · Cited by 1
Self-citationPsychedelics and Autism Therapy: A Review of Current Research and Future Directions
Gondi, C. S., Gnanamony, M., Gondi, T. P., Nersesyan, L., & Demirkhanyan, L. H. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040417
Khosravi, M., Berardis, D. D., & Tusconi, M. (2026) · Mental Wellness · doi:10.4081/mw.2026.40
Psychedelics: Future Therapeutics in Major Depression?
Olivier, B., & Olivier, J. D. A. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-981-95-6872-7_25
Mallard, A. J., Broussard, M., Zeifman, R. J., Espinoza, D., Cloutier, S. A., Ross, S., Bogenschutz, M. P., & Pagni, B. A. (2026) · Journal of Humanistic Psychology · doi:10.1177/00221678261442571
Self-citationNayak, S. M., Sepeda, N. D., Dick, M. N., Tiwari, P., Zahid, Z., Sayalı, C., Weiss, B., Yaden, D. B., Garcia‐Romeu, A., Barnett, B. S., et al. (2026) · medRxiv · doi:10.64898/2026.04.28.26351625
Self-citationD’Amelio, T. A., Garbagnoli, T. G., Cuello, J. R., Lewis-Healey, E., Pallavicini, C., Cavanna, F., Bruno, N. M., de la Fuente, L. A., Muller, S. A., Copa, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.30.721872
Editorial: Case reports in psychopharmacology, volume IV
Štuhec, M., & Ciano, P. D. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1861985
Carhart-Harris, R. L., Zeifman, R. J., Pasquini, L., Nandi, B., Rohani-Shukla, C., Suseelan, S., Mediano, P. A. M., Rosas, F. C. W., Timmermann, C., Kettner, H., et al. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1875339
“In comparison, the evidence for the safety and efficacy of high-dose psychedelic therapy for mental health improvement is weighty and compelling (Rieser et al., 2025; Carhart-Harris et al., 2021; Raison et al., 2023).”
Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes
Dwiel, L. L., Prina, M. L., Bragg, E. M., Drucker, L. L., Reduron, L. R., Luikart, B. W., & Doucette, W. T. (2026) · Brain stimulation · doi:10.1016/j.brs.2026.103130
Thulasingam, M., & Vellapandian, C. (2026) · Current Drug Therapy · doi:10.2174/0115748855435564251207185418
Can Childhood be Used as a Model to Understand the Effects of Psychedelics?
Hurwitz, E. S., Dean, J. G., & Walker, C. M. (2026) · Topics in Cognitive Science · doi:10.1111/tops.70058
Bu, F., Qin, L., Zi-yang, L. O. U., Xie, Y., Zhang, S. Z., Xiong, L., & Wen, Y. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s609327
Hood, A., & Elkins, G. R. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00507 · Cited by 2
Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache
Brendstrup‐Brix, K., Ozenne, B., Fisher, P. M., Stenbæk, D. S., Petersen, A. S., Armand, S., McCulloch, D. E.-W., Marstrand-Joergensen, M. R., Larsen, S. M. U., Johansen, A., et al. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261449380
Tortajada, J. J., Bulduk, B. K., Alfonso-Landete, B., Barriga, P. A., Ballvé, B., Garrabou, G., Vilella, E., Alonso, Y., Valiente-Pallejà, A., & Martorell, L. (2026) · General Psychiatry · doi:10.1002/gps3.70023
Kelly, C. M., Fradet, M., Bostian, C. M., Donnelly, A. J., Ellis, S., Ostacher, M. J., Aaronson, S., & Suppes, T. M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122063
Boehnke, K. F., Pouyan, N., & Aday, J. S. (2026) · Drugs · doi:10.1007/s40265-026-02339-5 · Cited by 2
From Resistance to Redesign—The Emerging Logic of Hybrid Care in Treatment-Resistant Depression
Mucci, F., Gurrieri, R., Bouanani, S., Gambini, M., Russomanno, G., & Marazziti, D. (2026) · Brain Sciences · doi:10.3390/brainsci16060612
“…in MDD using MADRS and centralized blinded raters found that a single 25 mg session plus psychological support produced rapid and sustained reductions over six weeks versus niacin as active placebo, reinforcing that current efficacy claims are articulated primarily on clinician-rated scales [28].”
Kervadec, E., Pauline, M., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Piolino, P., Benyamina, A., Roméo, B., & Hacquet, R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111770
Zhou, Y., Fan, J., Cao, L., Li, X., Dong, Y., Fang, S., Wu, Y., & Gu, S. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106866
Labra-Lorenzana, A., Lima-Sánchez, D. N., Delaflor-Wagner, C. A., Martínez-Hernández, D. G., Ramos-Jiménez, C., & Toledo-Lozano, C. G. (2026) · Psychiatry International · doi:10.3390/psychiatryint7030137
“Case-wise diagnostics flagged residual influence from Carhart-Harris [18] within subjects, and one Raison [16] effect size; no further exclusions were made.”
InfluentialLeeman, L., Armstrong, M., Menashi, D., Nayo-Washington, H., Marseille, E. A., Herrera, J., Romero, C., & Page‐Reeves, J. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1845943
“Psychedelic-assisted therapy is supported by a growing evidence base showing rapid and often sustained improvements in difficult-to-treat conditions, such as PTSD, depression, and substance use disorders (3–5).”
Cannabis, Psychedelics, and Other Substance Use to Manage Premenstrual Symptoms: A Survey Study
Nazareth, M., Paone, V., Yaden, M. E., Getachew, A., & Hantsoo, L. V. (2026) · Journal of Women s Health · doi:10.1177/15409996261459360
Psychedelics, the media portrayal and large-language model evaluations
Clelland, C. L. T. (2026) · BJPsych Open · doi:10.1192/bjo.2026.12025
Bray, E., Glatfelter, G. C., Maitland, A. D., Gonzalez, N. R., Walther, D. M., Yacoub, J., Baumann, M. H., & von Salm, J. L. (2026) · ACS Omega · doi:10.1021/acsomega.6c02996
Guidetti, C., D, M. F. M., & Papakostas, G. I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03722-0 · Cited by 1
Brar, P. S., Price, R. B., Ross, S., Tofighi, B., & Sarpal, D. K. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456191
“…naturally produced species of fungi, which has been examined as a treatment for a range of psychiatric conditions (Bogenschutz et al., 2022; Carhart-Harris et al., 2021; Davis et al., 2021a; Goodwin et al., 2022; Griffiths et al., 2016; Moreno et al., 2006; Raison et al., 2023; Ross et al., 2016).”
Self-citationThe purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review
Ferreira, F. G. D. P., Fernandes, J. A. B., Filev, R., da Silveira, D. X., & Fidalgo, T. M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261453850
Estela-Fernandez, C. A., Elsheikh, R. M. Y., Beatrice, D. F., Alhendal, A. A., Ewe, C. I., Montesinos, S. Y., Wensel, J., Mishra, A. P., Yousif, A. A., & Ali, H. T. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00584-4
CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder
Pasławski, W., Doyon, D., Ekman, C. J., Yngwe, H., Mamula, D., Zarȩba-Pasławska, J., Beckman, M., Xu, Q., Hökfelt, T., Tiger, M., et al. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02490-3
Psychedelics produce enduring enhancement of reward responsiveness in male rats
Thomas, C. W., LaMalfa, K. S., Whelan, T. P., Blackmore, T., Golden, C. T., Pizzagalli, D. A., Bergman, J., Gilmour, G., & Kangas, B. D. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02475-2 · Cited by 1
Hörnqvist, N. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00505
Gould, T. D., Mathew, S. J., D, M. F. M., & Shekhar, A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261456206 · Cited by 1
“Like ketamine, serotonergic psychedelics, such as psilocybin, have demonstrated rapid and long-lasting antidepressant effects following 1 or 2 doses (Carhart-Harris and Goodwin, 2017; Griffiths et al., 2016; Goodwin et al., 2022; Raison et al., 2023).”
Los, A. P. M., Szkodziński, K., Jakubczyk, I., Maternia, J., Majowicz-Czaszyńska, K. B., Pempuś, W., Król, N., Tomaszek, B., Blok, A., Wiater, D., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5755
“As demonstrated by Goodwin et al. and Raison et al., reported adverse effects are generally mild and transient, including headache, nausea and temporary increases in blood pressure (Goodwin et al., 2023; Raison et al., 2023).”
Averill, L. A., & Neitzke‐Spruill, L. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260006
The Gut–Brain Axis in Ganoderma lucidum’s Antidepressant Effects in Cancer Comorbidity: A Review
Du, X.-Y., Bu, F., & Ling, Z. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101731
Cellular mechanisms of serotonergic psychedelics - apical hypercontextualisation
Kaup, K., Jiménez, J. H., & Aru, J. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106876
Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping review
Vucak, N., Bruno, R., Quealy, J. J., Casimaty, J. G., Rossell, S. L., Castle, D. J., & Acevedo, N. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100030
Wang, Z., Daily, J. E., & Adams, D. R. (2026) · Research Square · doi:10.21203/rs.3.rs-10120004/v1
Sams, C. H., Davis, J., Ramdas, A., Delgoda, R., Vidot, D. C., Reid, M., & Haye, W. D. L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1876189
“However, the degree to which expectancy effects, blinding limitations, and therapeutic context in fl uence outcomes following higher therapeutic-doses of psilocy-bin remains an active area of investigation (41).”
Mapping excitatory synaptic plasticity evoked by single-dose psilocybin in micePreprint
Li, Z., Weber, C., Sellitti, F., & Simmler, L. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.31.741703
Berkovitch, L., & Charif, S. (2025) · Elsevier eBooks · doi:10.1016/b978-2-294-78794-2.00074-9
Depression und andere affektive Erkrankungen
Mertens, L. J., & Spangemacher, M. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00011-3
Feasibility and tolerability of psilocybin for phantom limb pain
Dean, J. G., Hurwitz, E. S., Furnish, T. J., Castellanos, J. P., McKinty, A., Farrell, B., Barrows, D., Peck, S. K., Trim, J., Samadhi, E., et al. (2026) · Journal of Pain · doi:10.1016/j.jpain.2026.106404
Sex-sensitive serotonergic signaling in psychedelic pharmacology
Nasini, S., Barzon, B., Casile, A., Richardson, B., Gobbi, G., & Comai, S. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.07.006 · Cited by 1
Spata, A., Sturges, J. W., & Earleywine, M. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2710057
Ke, X., Du, X., & Wang, X. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03816-9
Potential Role of Psychedelics in the Treatment of Depressive Disorder
Wang, S., & Bahk, W.-M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_12
Kruger, D. J., Gillis‐Smith, P., Aday, J. S., Barron, J., Herberholz, M., & Boehnke, K. F. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100034
Anghel, T., Cojocaru, A., Hogea, L., Costea, I., Marinca, A., Dumache, R., Nussbaum, L. A., & Trăilă, I.-A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166228
“Goodwin et al. identified the 25 mg dose as the most effective therapeutic regimen in patients with TRD across 22 international sites [36], while Raison et al. demonstrated rapid antidepressant effects occurring within eight days of administration [38].”
Metadata
- Authors
- Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., Gukasyan, N., Nayak, S. M., Hu, X., O’Donnell, K. C., Kelmendi, B., Sloshower, J., Penn, A. D., Bradley, E., Kelly, D. F., Mletzko, T., Nicholas, C. R., Hutson, P. R., Tarpley, G., Utzinger, M., Lenoch, K., Warchol, K., Gapasin, T., Davis, M. C., Nelson-Douthit, C., Wilson, S., Brown, C., Linton, W., Johnson, M. W., Ross, S., & Griffiths, R. R.
- Affiliations
- Usona Institute (US)
- Yale University (US)
- San Francisco VA Medical Center (US)
- Pacific Neuroscience Institute, Santa Monica, California
- Emory University (US)
- University of Wisconsin–Madison (US)
- Center for Psychedelic Research, Segal Trials, Lauderhill, Florida
- Hassman Research Institute (US)
- Flourish Research, Chicago, Illinois
- University of Utah (US)
- Johns Hopkins University (US)
- NYU Langone Health (US)
- University of California, San Francisco (US)
- Usona Institute, Fitchburg, Wisconsin
- Emmes (United States) (US)
- Corresponding author
- Raison, Charles L.
- ORCID
- Raison, Charles L.
- Sanacora, Gerard
- Woolley, Joshua
- Heinzerling, Keith
- Dunlop, Boadie W.
- Brown, Randall T.
- Trivedi, Rupal P.
- Robison, Reid
- Gukasyan, Natalie
- Nayak, Sandeep M.
- O’Donnell, Kelley C.
- Kelmendi, Benjamin
- Sloshower, Jordan
- Penn, Andrew D.
- Bradley, Ellen
- Kelly, Daniel F.
- Mletzko, Tanja
- Nicholas, Christopher R.
- Hutson, Paul R.
- Brown, Carrie
- Johnson, Matthew W.
- Ross, Stephen
- Griffiths, Roland R.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2023-09-05
- Volume
- 330
- Issue
- 9
- Pages
- 843
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC10472268
- OpenAlex
- W4386305655
- Cited by
- 545
- References
- 35
- Citations by year
- 2026: 165 · 2025: 212 · 2024: 152 · 2023: 16
- FWCI
- 158.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Center for Advancing Translational Sciences
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- psilocybin, major depressive disorder, antidepressant effects, psychological support, depression remission, sustained response, adverse events, antidepressant safety, psychedelic therapy, Sheehan Disability Scale, Montgomery-Asberg Depression Rating Scale, treatment durability
- MeSH terms
- Adult, Major Depressive Disorder, Female, Hallucinogens, Humans, Male, Mental Health, Niacin, Psilocybin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
